Essential Medicines at the National Level: The Global Asthma Network's Essential Asthma Medicines Survey 2014

Overview

Journal Int J Environ Res Public Health

Publisher MDPI

Specialties Environmental Health
Public Health

Date 2019 Feb 23

PMID 30791442

Citations 6

Authors

Karen Bissell

Philippa Ellwood

Eamon Ellwood

Chen-Yuan Chiang

Guy B Marks

Asma El Sony

Innes Asher

Nils Billo

Christophe Perrin

Affiliations

Soon will be listed here.

Abstract

Patients with asthma need uninterrupted supplies of affordable, quality-assured essential medicines. However, access in many low- and middle-income countries (LMICs) is limited. The World Health Organization (WHO) Non-Communicable Disease (NCD) Global Action Plan 2013⁻2020 sets an 80% target for essential NCD medicines' availability. Poor access is partly due to medicines not being included on the national Essential Medicines Lists (EML) and/or National Reimbursement Lists (NRL) which guide the provision of free/subsidised medicines. We aimed to determine how many countries have essential asthma medicines on their EML and NRL, which essential asthma medicines, and whether surveys might monitor progress. A cross-sectional survey in 2013⁻2015 of Global Asthma Network principal investigators generated 111/120 (93%) responses-41 high-income countries and territories (HICs); 70 LMICs. Patients in HICs with NRL are best served (91% HICs included ICS (inhaled corticosteroids) and salbutamol). Patients in the 24 (34%) LMICs with no NRL and the 14 (30%) LMICs with an NRL, however no ICS are likely to have very poor access to affordable, quality-assured ICS. Many LMICs do not have essential asthma medicines on their EML or NRL. Technical guidance and advocacy for policy change is required. Improving access to these medicines will improve the health system's capacity to address NCDs.

Citing Articles

Pharmacoequity in Allergy-Immunology: Disparities in Access to Medications for Allergic Diseases and Proposed Solutions in the United States and Globally.

Maldonado-Puebla M, Akenroye A, Busby J, Cardet J, Louisias M J Allergy Clin Immunol Pract. 2023; 12(2):272-280.

PMID: 37951413 PMC: 10922722. DOI: 10.1016/j.jaip.2023.11.005.

Gaps in asthma diagnosis and treatment in low- and middle-income countries.

Barne M Front Allergy. 2023; 4:1240259.

PMID: 37937199 PMC: 10627233. DOI: 10.3389/falgy.2023.1240259.

Asthma management and control in children, adolescents, and adults in 25 countries: a Global Asthma Network Phase I cross-sectional study.

Garcia-Marcos L, Chiang C, Asher M, Marks G, El Sony A, Masekela R Lancet Glob Health. 2023; 11(2):e218-e228.

PMID: 36669806 PMC: 9885426. DOI: 10.1016/S2214-109X(22)00506-X.

Implementing Single-Pill Combination Therapy for Hypertension: A Scoping Review of Key Health System Requirements in 30 Low- and Middle-Income Countries.

Bruyn E, Nguyen L, Schutte A, Murphy A, Perel P, Webster R Glob Heart. 2022; 17(1):6.

PMID: 35174047 PMC: 8796691. DOI: 10.5334/gh.1087.

Global Asthma Network Phase I Surveillance: Geographical Coverage and Response Rates.

Ellwood P, Ellwood E, Rutter C, Perez-Fernandez V, Morales E, Garcia-Marcos L J Clin Med. 2020; 9(11).

PMID: 33212975 PMC: 7698565. DOI: 10.3390/jcm9113688.

References

Robertson J, Mace C, Forte G, de Joncheere K, Beran D . Medicines availability for non-communicable diseases: the case for standardized monitoring. Global Health. 2015; 11:18. PMC: 4427979. DOI: 10.1186/s12992-015-0105-0. View

. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017; 390(10100):1151-1210. PMC: 5605883. DOI: 10.1016/S0140-6736(17)32152-9. View

El Sony A, Chiang C, Malik E, Hassanain S, Hussien H, Khamis A . Standard case management of asthma in Sudan: a pilot project. Public Health Action. 2015; 3(3):247-52. PMC: 4463127. DOI: 10.5588/pha.13.0019. View

Eom G, Grootendorst P, Duffin J . The case for an essential medicines list for Canada. CMAJ. 2016; 188(17-18):E499-E503. PMC: 5135527. DOI: 10.1503/cmaj.160134. View

FitzGerald J, Sadatsafavi M . The importance of measuring asthma control in emerging economies. Int J Tuberc Lung Dis. 2014; 18(3):254. DOI: 10.5588/ijtld.14.0096. View

Kan X, Chiang C, Enarson D, Rao H, Chen Q, Ait-Khaled N . Asthma as a hidden disease in rural China: opportunities and challenges of standard case management. Public Health Action. 2015; 2(3):87-91. PMC: 4463046. DOI: 10.5588/pha.12.0025. View

. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017; 390(10100):1211-1259. PMC: 5605509. DOI: 10.1016/S0140-6736(17)32154-2. View

Perehudoff S, Laing R, Hogerzeil H . Access to essential medicines in national constitutions. Bull World Health Organ. 2010; 88(11):800. PMC: 2971519. DOI: 10.2471/BLT.10.078733. View

Wirtz V, Hogerzeil H, Gray A, Bigdeli M, de Joncheere C, Ewen M . Essential medicines for universal health coverage. Lancet. 2016; 389(10067):403-476. PMC: 7159295. DOI: 10.1016/S0140-6736(16)31599-9. View

10.

Duong M, Moles R, Chaar B, Chen T . Essential Medicines in a High Income Country: Essential to Whom?. PLoS One. 2015; 10(12):e0143654. PMC: 4674059. DOI: 10.1371/journal.pone.0143654. View

11.

Gray A, Wirtz V, t Hoen E, Reich M, Hogerzeil H . Essential medicines are still essential. Lancet. 2015; 386(10004):1601-3. DOI: 10.1016/S0140-6736(15)00514-0. View

12.

Davidsen J, Sondergaard J, Hallas J, Siersted H, Knudsen T, Lykkegaard J . Impact of socioeconomic status on the use of inhaled corticosteroids in young adult asthmatics. Respir Med. 2010; 105(5):683-90. DOI: 10.1016/j.rmed.2010.11.009. View

13.

Ravinetto R, Vandenbergh D, Mace C, Pouget C, Renchon B, Rigal J . Fighting poor-quality medicines in low- and middle-income countries: the importance of advocacy and pedagogy. J Pharm Policy Pract. 2016; 9:36. PMC: 5105267. DOI: 10.1186/s40545-016-0088-0. View

14.

Pearce N, Asher I, Billo N, Bissell K, Ellwood P, El Sony A . Asthma in the global NCD agenda: a neglected epidemic. Lancet Respir Med. 2014; 1(2):96-8. DOI: 10.1016/S2213-2600(13)70023-7. View

15.

Beran D, Zar H, Perrin C, Menezes A, Burney P . Burden of asthma and chronic obstructive pulmonary disease and access to essential medicines in low-income and middle-income countries. Lancet Respir Med. 2015; 3(2):159-170. DOI: 10.1016/S2213-2600(15)00004-1. View

16.

Ade G, Gninafon M, Tawo L, Ait-Khaled N, Enarson D, Chiang C . Management of asthma in Benin: the challenge of loss to follow-up. Public Health Action. 2015; 3(1):76-80. PMC: 4463093. DOI: 10.5588/pha.12.0080. View

17.

Laing R, Waning B, Gray A, Ford N, Hoen E . 25 years of the WHO essential medicines lists: progress and challenges. Lancet. 2003; 361(9370):1723-9. DOI: 10.1016/S0140-6736(03)13375-2. View

18.

Enarson D . Fostering a spirit of critical thinking: the ISAAC story. Int J Tuberc Lung Dis. 2005; 9(1):1. View

19.

Lai C, Beasley R, Crane J, Foliaki S, Shah J, Weiland S . Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009; 64(6):476-83. DOI: 10.1136/thx.2008.106609. View

20.

Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R . Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet. 2008; 373(9659):240-9. DOI: 10.1016/S0140-6736(08)61762-6. View